A Study of Mapatumumab in Combination With Paclitaxel and Carboplatin in Subjects With Non-small Cell Lung Cancer

Completed · Phase 2

Conditions studied: Non Small Cell Lung Cancer

In brief

The purpose of this study is to evaluate the efficacy (disease response) and safety of mapatumumab in combination with carboplatin and paclitaxel as first line therapy in subjects with advanced non-small cell lung cancer (NSCLC).

Key facts

Study ID

NCT00583830

Run by

Human Genome Sciences Inc.

People needed

111

Starts

2007-01-01

Expected to finish

2011-02-01

Last updated by the study team

2013-08-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with histologically or cytologically confirmed stage IIIB or stage IV advanced primary non-small cell lung cancinoma
• Age 18 years or older

You may not qualify if…

• Received investigational (not yet approved by a regulatory authority) or non-investigational agent to treat Lung Cancer
• Received radiation therapy within 4 weeks before randomization
• Major surgery within 4 weeks before randomization
• Minor surgery within 2 weeks before randomizaiton
• Systemic steroids within 1 week before randomization
• Any grade 2 or greater neuropathy
• History of severe (Grade 4) hypersensitivity reaction to products containing Cremophor EL (cyclosporine, teniposide)
• History of any infection requiring hospitalization or antibiotics within 2 weeks before randomization
• Known brain or spinal cord metastases
• History of other cancers within 5 years before randomization
• Known HIV, hepatitis-B or hepatitis-C infection
• Pregnant or breast-feeding women
• Previously treated with Mapatumumab

Where it is running

• Birmingham Hematology and Oncology Associates, LLC — Birmingham, Alabama, United States
• Desert Hematology Oncology Medical Group, Inc. — Rancho Mirage, California, United States
• University of Colorado Health Sciences Center — Aurora, Colorado, United States
• Osceola Cancer Center — Kissimmee, Florida, United States
• Palm Beach Cancer Institute — West Palm Beach, Florida, United States
• Rush University Medical Center — Chicago, Illinois, United States
• LaGrange Oncology Associates — LaGrange, Illinois, United States
• Orchard Research, LLC — Skokie, Illinois, United States
• Kentuckiana Cancer Institute, PLLC — Louisville, Kentucky, United States
• University of Maryland, Greenebaum Cancer Center — Baltimore, Maryland, United States
• Chevy Chase Health Care — Chevy Chase, Maryland, United States
• Hackensack University Medical Center — Hackensack, New Jersey, United States
• Medical University of South Carolina: Hollings Cancer Center — Charleston, South Carolina, United States
• The Sarah Cannon Cancer Center — Nashville, Tennessee, United States
• UT Health Science Center at San Antonio, Be Well Center — San Antonio, Texas, United States
• Fairfax-Northern Virginia Hematology Oncology, PC — Fairfax, Virginia, United States
• Charite - Campus Mitte, Universitätsmedizin Berlin, Abteilung Onkologie und Hämatologie — Berlin, Germany
• Universitätsmedizin Berlin, Centrum für Innere Medizin — Berlin, Germany
• Asklepios Fachkliniken München-Gauting — Gauting, Germany
• Krankenhaus Großhansdorf — Großhansdorf, Germany
• Krankenhaus Martha-Maria Halle-Dölau — Halle, Germany
• Universitätsklinik Magdeburg, Klinik für Kardiologie, Angiologie und Pneumologie — Magdeburg, Germany
• Klinikum der Johannes-Gutenberg-Universität Mainz — Mainz, Germany
• Universitätsklinikum Mannheim, Chirurgische Klinik — Mannheim, Germany
• Pius-Hospital — Oldenburg, Germany

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.